12:30 PM EDT, 07/24/2024 (MT Newswires) -- GSK (GSK) said Wednesday that Health Canada has fully approved Jemperli, or dostarlimab, as a monotherapy for adults with recurrent or advanced mismatch repair deficient/microsatellite instability-high endometrial cancer.

The full approval of Jemperli, which was previously issued a notice of compliance, was based on additional data from a phase 1 trial that showed an objective response rate of 45.5% in patients, the company said.

Price: 39.17, Change: +0.33, Percent Change: +0.85